Cabaletta Bio, Inc. (CABA)

Market Cap	55.82M
Revenue (ttm)	n/a
Net Income (ttm)	-115.86M
Shares Out	50.74M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	508,710
Open	1.110
Previous Close	1.080
Day's Range	1.080 - 1.130
52-Week Range	0.986 - 16.360
Beta	2.44
Analysts	Strong Buy
Price Target	21.00 (+1,791.89%)
Earnings Date	May 14, 2025

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: CABA
• Website: https://www.cabalettabio.com

Analyst Forecast

According to 8 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 1,791.89% from the latest price.

Price Target

$21.0

(1,791.89% upside)

Analyst Consensus: Strong Buy